Agomab Reports Positive Phase 2a Results for Ontunisertib in Fibrostenosing Crohn’s Disease

FDA Expands RINVOQ® Indication for Inflammatory Bowel Disease

AstraZeneca Partners with Immunai in $85M AI-Driven IBD Deal

Phase 4 Study: Vedolizumab More Effective in Early Crohn’s Disease

CU Anschutz Study Links MAIT Cells to Gut Inflammation

SMC Approves TREMFYA® for Crohn’s Disease and Ulcerative Colitis

MRC Researchers Uncover Cell Mechanism Behind Crohn’s Fistulas

Numab and Kaken Partner on First-in-Class Multispecific Antibody for IBD

Joshua Korzenik

Physician Brigham and Women's Hospital

Wednesday 1st April 2026

Roundtable Discussion: Overcoming Barriers to Move IBD Biomarkers into Validated Diagnostics that Impact Patient Care & Future Therapies

2:30 pm

Define the role of diagnostics in IBD to accelerate precision medicine adoption
Stepwise development from discovery to clinical validation and commercialization
Address regulatory and commercial hurdles so validated tests can reach patients, not just publications